10-K: Spectral AI Reports Full Year 2024 Results, Highlights UKCA Marking and Government Funding

Spectral AI's 2024 annual report reveals a focus on DeepView System development, UKCA marking achievement, and reliance on government funding, with a net loss of $15.3 million.

Summary

• Spectral AI, an AI-driven predictive medical diagnostics company, released its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company incurred a net loss of $15.3 million in 2024, compared to a net loss of $20.9 million in 2023.
• Spectral AI's cash balance as of December 31, 2024, was $5.2 million.
• The company's primary focus is the development of its DeepView System, which received UKCA marking for burn indications.
• Spectral AI relies heavily on government funding, particularly from BARDA, which has awarded the company approximately $272.9 million since 2013.
• A new contract with BARDA in September 2023 provides up to $150.0 million in additional funding.
• The company anticipates initial sales in the UK to begin in 2025, pending regulatory market authorizations.
• Spectral AI intends to submit a De Novo application to the FDA for market authorization of the burn application by the end of the first half of 2025.
• As of December 31, 2024, the company's proprietary database contains approximately 340 billion pixels of image data.
• The company is also developing DeepView SnapShot M, a handheld diagnostic tool, with funding from the DHA and MTEC.
• Spectral AI is developing 3-D software-based wound measurement technology for its DeepView System.
• The company's current focus is to fulfill contractual obligations and meet milestones under its BARDA PBS contract and to pursue other indications for the commercialization of the DeepView System in the UK, United States and EU.
• The company is working towards obtaining the CE Mark and UKCA certificates to allow market access in the EU and UK, respectively.
• The company has identified a material weakness in its internal control over financial reporting related to deficiencies in its controls over the accounting for complex equity arrangements, financial statement close process and in the design and operation of internal controls involving accruals and unbilled revenue.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments like the UKCA marking and continued government funding, the significant net loss and identified material weakness in internal controls temper the overall outlook. The company's reliance on future capital raises also adds uncertainty.

Positives

• The company received UKCA marking for its DeepView System for burn indications.
• The company has been awarded approximately $281.5 million in funding from government contracts since 2013, with $272.9 million from BARDA.
• A new BARDA contract provides up to $150.0 million in additional funding.
• The company is developing DeepView SnapShot M with over $7.2 million in funding.
• The company's proprietary database for burns contains approximately 340 billion pixels of image data.

Negatives

• Spectral AI incurred a net loss of $15.3 million in 2024.
• The company's cash balance was $5.2 million as of December 31, 2024.
• The company has identified a material weakness in its internal control over financial reporting related to deficiencies in its controls over the accounting for complex equity arrangements, financial statement close process and in the design and operation of internal controls involving accruals and unbilled revenue.

Risks

• The company has incurred significant losses since inception and may not be able to achieve significant revenues or profitability.
• The company is devoting substantially all of its efforts towards research and development of its DeepView System.
• The company depends on government funding, which if lost or reduced, could have a material adverse effect on research and development activities and the ability to commercialize the DeepView technology.
• The regulatory review process is expensive, time-consuming, and uncertain and the company may be unable to obtain clearance, approval, De Novo classification, or certification for the DeepView technology.
• The company may experience significant delays in completing clinical trials, which could prevent or significantly delay the targeted product launch timeframe and impair the company's viability and business plan.
• The company may need additional funding to finance planned operations and may not be able to raise capital when needed, which could force the company to delay clinical trials necessary to market products or delay establishment of sales and marketing capabilities or other activities necessary to commercialize products.
• If the company fails to maintain proper and effective internal controls over financial reporting, the ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in the company's financial reporting and the trading price of the Common Stock may decline.

Future Outlook

Subject to receipt of necessary regulatory market authorizations, the company intends to initially sell the DeepView System throughout the United States and the UK for its burn indication, with commercial sales expected to commence in 2025 in the UK and in 2026 in the United States.

Industry Context

The document highlights Spectral AI's position in the predictive wound-healing diagnostic market, emphasizing the lack of comparable AI-enabled technologies. It acknowledges competition from companies offering wound imaging systems and conventional assessment methods, but positions DeepView as a disruptive technology with the potential to create a new diagnostic market.

Comparison to Industry Standards

• The document states that there are no comparable digital wound healing predictive medical diagnostic products that provide clinicians with an objective and immediate assessment of a wound's future healing potential that benefit from the application of AI.
• The document mentions several companies that have developed wound imaging systems for wounds; however, these systems incorporate technology such as spatial frequency domain imaging, thermal imaging, photographic documentation, hyperspectral imaging, and near-infrared imaging that provide physiologic data to the physician.
• The document states that the majority of systems in the wound care space are merely documentation tools that record measurements of the wound for health record purposes and still rely upon subjective clinician opinion for treatment decisions.

Related Party Transactions

• Spectral IP received a $1.0 million investment from an affiliate of its largest shareholder for the development of its artificial intelligence intellectual property portfolio.
• The holder of the Spectral IP Note exercised a number of conversion rights throughout the fourth quarter of 2024 for the full conversion of the Spectral IP Note in exchange for a total of 540,996 shares of the Companys common stock, which represents a 5.00% discount to the closing price of the Companys shares of Common Stock on the day prior to the date of notice of the holders exercise of its conversion right.

Stakeholder Impact

• Shareholders: Dilution from potential equity offerings and warrant exercises.
• Employees: Continued employment and potential for new hires, particularly in operations, sales, marketing, and government contracts.
• Customers: Potential for improved wound care assessment and treatment decisions with the DeepView System.
• Suppliers: Continued business relationships with contract manufacturers and suppliers.
• Creditors: Repayment of existing debt and potential for new debt financing.

Next Steps

• Fulfill contractual obligations and meet milestones under the BARDA PBS contract.
• Pursue other indications for the commercialization of the DeepView System in the UK, United States and EU.
• Submit a De Novo application to the FDA for market authorization of the burn application by the end of the first half of 2025.
• Schedule the DeepView System Technical Documentation audit necessary to obtain the CE Mark and UKCA certificates to allow market access in the EU and UK, respectively.
• Continue to implement measures designed to improve internal control over financial reporting to remediate the material weakness.

Key Dates

Keywords

Spectral AI, DeepView System, BARDA, UKCA marking, FDA, AI, wound healing, government funding, clinical trials, De Novo application, MTEC, DHA, financial results, risk factors, intellectual property